Company profile
Azitra, Inc.
AMEX: AZTR · Healthcare · Biotechnology
PublicHQ Branford, CTCIK 0001701478Reports USD
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
29DFH 34DQ 33GM 11SS 24
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, filing timeliness · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$11.0M
Employees
13
as of 2026-08-25
Market cap
$1.6M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$11.0M-$11.0M2025
Operating income-$11.0M-$11.0M2025
Total assets$5.0M$5.0M2025
Liabilities$1.2M$1.2M2025
Equity$3.8M$3.8M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Azitra, Inc.’s revenue?
Azitra, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Decoy Therapeutics Inc.31DProtagenic Therapeutics, Inc.——Welsis Corp.20DAcro Biomedical Co., Ltd.16DCity View Green Holdings Inc.——Anything Technologies Media, Inc.33DKey facts
CEOFrancisco D. Salva
SectorHealthcare
IndustryBiotechnology
HeadquartersBranford, CT
ExchangeAMEX: AZTR
Employees13
IPO date2023-06-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.